journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Drug Discovery

journal
https://www.readbyqxmd.com/read/27917682/the-preclinical-discovery-and-development-of-bortezomib-for-the-treatment-of-mantle-cell-lymphoma
#1
Richard Arkwright, Tri Minh Pham, Jeffrey A Zonder, Q Ping Dou
Introduction- Mantle cell lymphoma (MCL) is an incurable, often aggressive B-cell malignancy. Bortezomib (BTZ), the 20S proteasome inhibitor was originally developed and approved for treatment of relapsed refractory multiple myeloma, and subsequently approved for treatment of MCL. BTZ's single-agent activity induces clinical responses in approximately one-third of relapsed MCL patients. BTZ-containing combination therapies have further improved the quality and duration of clinical responses compared to standard chemotherapies in previously untreated MCL patients...
December 3, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27911223/advances-in-capillary-electrophoresis-and-the-implications-for-drug-discovery
#2
Claire M Ouimet, Cara I D'Amico, Robert T Kennedy
Many screening platforms are prone to assay interferences that can be avoided by directly measuring the target or enzymatic product. Capillary electrophoresis (CE) and microchip electrophoresis (MCE) have been applied in a variety of formats to drug discovery. CE provides direct detection of the product allowing for the identification of some forms of assay interference. The high efficiency, rapid separations, and low volume requirements make CE amenable to drug discovery. Areas Covered: This article describes advances in capillary electrophoresis throughput, sample introduction, and target assays as they pertain to drug discovery and screening...
December 2, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27883294/drug-discovery-beyond-the-rule-of-5-opportunities-and-challenges
#3
Bradley C Doak, Jan Kihlberg
No abstract text is available yet for this article.
November 24, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27866431/microrna-targeted-therapeutics-for-lung-cancer-treatment
#4
Jing Xue, Jiali Yang, Meihui Luo, William C Cho, Xiaoming Liu
Lung cancer is one of the leading causes of cancer-related mortality worldwide. MicroRNAs (miRNAs) are endogenous non-coding small RNAs that repress the expression of a broad array of target genes. Many efforts have been made to therapeutically target miRNAs in cancer treatments using miRNA mimics and miRNA antagonists. Areas covered: This article summarizes the recent findings with the role of miRNAs in lung cancer, and discusses the potential and challenges of developing miRNA-targeted therapeutics in this dreadful disease...
November 20, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27838932/the-need-for-fundamental-reforms-in-the-pain-research-field-to-develop-innovative-drugs
#5
Yukinori Nagakura
Chronic pain is a major healthcare issue owing to its high prevalence, significant physical and emotional burden on the patients, and huge financial burden on the society. The efficacy of currently available medications is unsatisfactory owing to their limited effect size and the low responder rate (less than 50%). Thus, there is a large unmet need for innovative therapies for chronic pain. Areas covered: In this review, the author points out the need for fundamental reforms in pain research. For the last several decades, drug discovery research has extensively focused on designing new therapies using animal models of chronic pain...
November 14, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27797589/targeting-of-amp-activated-protein-kinase-prospects-for-computer-aided-drug-design
#6
Joungmok Kim, Goowon Yang, Joohun Ha
Dysregulation of energy homeostasis has been implicated in a number of human chronic diseases including diabetes, obesity, cancer, and inflammation. Given the functional attributes as a central regulator of energy homeostasis, AMP-activated protein kinase (AMPK) is emerging as a therapeutic target for these diseases, and lines of evidence have highlighted the need for rational and robust screening systems for identifying specific AMPK modulators with a therapeutic potential for preventing and/or curing these diseases...
November 14, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27797587/the-current-status-and-future-directions-of-hepatitis-b-antiviral-drug-discovery
#7
Liudi Tang, Qiong Zhao, Shuo Wu, Junjun Cheng, Jinhong Chang, Ju-Tao Guo
The current standard care of chronic hepatitis B fails to induce a durable off-drug control of hepatitis B virus (HBV) replication in the majority of treated patients. The primary reasons are its inability to eliminate the covalently closed circular (ccc) DNA, the nuclear form of HBV genome, and restoration of the dysfunctional host antiviral immune response against the virus. Accordingly, discovery and development of therapeutics to completely stop HBV replication, eliminate or functionally inactivate cccDNA as well as activate a functional antiviral immune response against HBV are the primary efforts for finding a cure for chronic hepatitis B...
November 11, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27783541/advances-in-structure-based-drug-discovery-of-carbonic-anhydrase-inhibitors
#8
Claudiu T Supuran
The enzyme carbonic anhydrase (CA, EC 4.2.1.1) is found in numerous organisms across the tree of life, with seven distinct classes known to date. CA inhibition can be exploited for the treatment of edema, glaucoma, seizures, obesity, cancer and infectious diseases. A myriad of CA inhibitor (CAI) classes and inhibition mechanisms have been identified over the past decade, mainly through structure-based drug design approaches. Five different CA inhibition mechanisms are presently known. Areas covered: Recent advances in structure-based CAI design are reviewed, with periodic table-based organization of inhibitor classes...
November 9, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27782770/new-experimental-models-of-the-blood-brain-barrier-for-cns-drug-discovery
#9
Mohammad A Kaisar, Ravi K Sajja, Shikha Prasad, Vinay V Abhyankar, Taylor Liles, Luca Cucullo
The blood-brain barrier (BBB) is a dynamic biological interface which actively controls the passage of substances between the blood and the central nervous system (CNS). From a biological and functional standpoint, the BBB plays a crucial role in maintaining brain homeostasis inasmuch that deterioration of BBB functions are prodromal to many CNS disorders. Conversely, the BBB hinders the delivery of drugs targeting the brain to treat a variety of neurological diseases. Area covered: This article reviews recent technological improvements and innovation in the field of BBB modeling including static and dynamic cell-based platforms, microfluidic systems and the use of stem cells and 3D printing technologies...
November 7, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27808589/challenges-for-drug-discovery-and-development-in-china
#10
Kam Lun Hon, Vivian W Y Lee
The drug development industry is restructuring worldwide in terms of the research and development process. As with pharmaceuticals in the west and worldwide, China faces major challenges for drug discovery and development. Areas covered. In this review, the authors discuss anti-cancer, anti-allergy, anti-infectious, and proprietary Chinese Medicines (pCM) for various chronic diseases (such as the allergic diseases: eczema, asthma and allergic rhinitis), which remain the contemporary therapeutic strategies that are being explored and developed...
November 3, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27797593/current-challenges-in-drug-discovery-for-tuberculosis
#11
Anuradha Kumar, Somsundaram Chettiar, Tanya Parish
No abstract text is available yet for this article.
October 31, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27784173/high-performance-enzyme-kinetics-of-turnover-activation-and-inhibition-for-translational-drug-discovery
#12
Rumin Zhang, Kenny Wong
Enzymes are the macromolecular catalysts of many living processes and represent a sizable proportion of all druggable biological targets. Enzymology has been practiced just over a century during which much progress has been made in both the identification of new enzymes and the development of novel methodologies for enzyme kinetics. Areas covered: This review aims to address several key practical aspects in enzyme kinetics in reference to translational drug discovery research. The authors first define what constitutes a high performance enzyme kinetic assay...
October 27, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27718641/discovery-and-optimization-of-peptide-macrocycles
#13
Andrew M White, David J Craik
Macrocyclic peptides are generally more resistant to proteolysis and often have higher potency than linear peptides and so they are excellent leads in drug design. Their study is significant because they offer potential as a new generation of drugs that are potent and specific, and thus might have fewer side effects than traditional small molecule drugs. Areas covered: This article covers macrocyclic drug leads based on nature-derived cyclic peptides as well as synthetic cyclic peptides and close derivatives...
October 10, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27712124/leveraging-allostery-to-improve-g-protein-coupled-receptor-gpcr-directed-therapeutics-cannabinoid-receptor-1-as-a-discovery-target
#14
David R Janero, Ganesh A Thakur
Allosteric modulators of G-protein coupled receptors (GPCRs) hold the promise of improved pharmacology and safety over typical orthosteric GPCR ligands. These features are particularly relevant to the cannabinoid receptor 1 (CB1R) GPCR, since typical orthosteric CB1R ligands are associated with adverse events that limit their translational potential. Areas covered: The contextual basis for applying allostery to CB1R is considered from pharmacological, drug-discovery, and medicinal standpoints. Rational design of small-molecule CB1R allosteric modulators as potential pharmacotherapeutics would be greatly facilitated by direct experimental characterization of structure-function correlates underlying the biological activity of chemically-diverse CB1R allosteric modulators, CB1R allosteric ligand-binding binding pockets, and amino acid contact residues critical to allosteric ligand engagement and activity...
October 7, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27704986/structure-based-discovery-and-binding-site-analysis-of-histamine-receptor-ligands
#15
Róbert Kiss, György M Keserű
The application of structure-based drug discovery in histamine receptor projects was previously hampered by the lack of experimental structures. The publication of the first X-ray structure of the histamine H1 receptor has been followed by several successful virtual screens and binding site analysis studies of H1-antihistamines. This structure together with several other recently solved aminergic G-protein coupled receptors (GPCRs) enabled the development of more realistic homology models for H2, H3 and H4 receptors...
October 5, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27701891/recent-advances-in-targeting-the-fatty-acid-biosynthetic-pathway-using-fatty-acid-synthase-inhibitors
#16
Thelma S Angeles, Robert L Hudkins
Elevated lipogenesis has been associated with a variety of diseases including obesity, cancer and nonalcoholic fatty liver disease (NAFLD). Fatty acid synthase (FASN) plays a pivotal role in de novo lipogenesis, making this multi-catalytic protein an attractive target for therapeutic intervention. Recently, the first FASN inhibitor successfully advanced through the drug development process and entered clinical evaluation in oncology. Areas covered: This review discusses the biological roles of FASN in three prominent disease areas: cancer, obesity-related disorders and non-alcoholic fatty liver disease...
October 5, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27700193/approaches-for-targeting-cancer-stem-cells-drug-resistance
#17
Roberta Rosa, Valentina D'Amato, Sabino De Placido, Roberto Bianco
Several reports have suggested that a population of undifferentiated cells known as cancer stem cells (CSCs), is responsible for cancer formation and maintenance. In the last decade, the presence of CSCs in solid cancers have been reported. Areas covered: This review summarizes the main approaches for targeting CSCs drug resistance. It is indeed known that CSCs may contribute to resistance to conventional chemotherapy, radiotherapy and targeted agents. Among the mechanisms by which CSCs escape anticancer therapies, removal of therapeutic agents by drug efflux pumps, enhanced DNA damage repair, activation of mitogenic/anti-apoptotic pathways; the main features of CSCs, stemness and EMT, are involved, as well as the capability to evade immune response...
October 4, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27635856/should-network-biology-be-used-for-drug-discovery
#18
Francisco Martínez-Jiménez, Marc A Marti-Renom
No abstract text is available yet for this article.
September 23, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27611363/centipede-venoms-as-a-source-of-drug-leads
#19
Eivind A B Undheim, Ronald A Jenner, Glenn F King
INTRODUCTION: Centipedes are one of the oldest and most successful lineages of venomous terrestrial predators. Despite their use for centuries in traditional medicine, centipede venoms remain poorly studied. However, recent work indicates that centipede venoms are highly complex chemical arsenals that are rich in disulfide-constrained peptides that have novel pharmacology and three-dimensional structure. AREAS COVERED: This review summarizes what is currently known about centipede venom proteins, with a focus on disulfide-rich peptides that have novel or unexpected pharmacology that might be useful from a therapeutic perspective...
September 9, 2016: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27689915/in-silico-frameworks-for-systematic-pre-clinical-screening-of-potential-anti-leukemia-therapeutics
#20
Matthew H Ung, Frederick S Varn, Chao Cheng
Leukemia is a collection of highly heterogeneous cancers that arise from neoplastic transformation and clonal expansion of immature hematopoietic cells. Post-treatment recurrence is high, especially among elderly patients, thus necessitating more effective treatment modalities. Development of novel anti-leukemic compounds relies heavily on traditional in vitro screens which require extensive resources and time. Therefore, integration of in silico screens prior to experimental validation can improve the efficiency of pre-clinical drug development...
December 2016: Expert Opinion on Drug Discovery
journal
journal
41534
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"